←Back to Expert Scholars
Translational Medicine / 转化医学Cancer Pharmacology, Early Phase Trials
David S. Hong
MD
🏢MD Anderson Cancer Center🌐USA
Deputy Chair, Department of Investigational Cancer Therapeutics
75
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
David Hong has led first-in-human studies of many targeted agents including early development of KRAS G12C inhibitors. He is a prolific principal investigator of early phase oncology trials at MD Anderson. His work has defined dosing and biomarker strategies for emerging precision oncology drugs.
Share:
🧪Research Fields 研究领域
phase I trials
KRAS inhibitors
targeted therapy
drug development
investigational therapeutics
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 David S. Hong 的研究动态
Follow David S. Hong's research updates
留下邮箱，当我们发布与 David S. Hong（MD Anderson Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment